Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses

3: MDT collaboration in NSCLC - Aligning oncologists, nurses, and patients to enhance EGFR inhibitor treatment pathways and supportive care

ASCO 2026: Comment: Multi-cancer earlier detection tests

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma

Bupropion shows benefit for cancer-related fatigue in cancer survivors

Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety

Short-term fasting linked to improved chemo response in advanced ovarian cancer

FMISO PET-guided radiation dose de-escalation maintains long-term outcomes in HPV-associated oropharyngeal cancer